NCT01552356 2026-03-18
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
6 trialsNCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00674024 2019-11-20
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT00450879 2015-03-25
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00929903 2013-09-30
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
National Cancer Institute (NCI)
Phase 1 Completed